ANT1034
ANT1034 is humanized anti-CD52 antibody. ANT1034 directs antibody dependent and complement dependent cell cytotoxicity, induces Apoptosis when cross-linked or in the presence of a cross-linking antibody. ANT1034 leads to increased survival in a SCID CD52 tumour xenograft model. ANT1034 can be used for the research of B cell malignancies.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human
CD52
ANT1034 (100 μg/ml; 72 hours) is more effective at directly inducing cell death (apoptosis/necrosis) in REH++ cells than Alemtuzumab (HY-P9948) in the presence of a crosslinking antibody[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fox Chase SCID mice (female, 8 per group, injected with 1×10⁶ Raji++ cells via tail-vein injection)[1]
-
Dosage:1, 10 mg/kg
-
Administration:i.p.; once daily on alternate days; 7 doses
-
Result:Increased mouse survival compared to alemtuzumab at 10 mg/kg; Showed superior survival enhancement even at the lower 1 mg/kg dose relative to alemtuzumab
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
ANT1034 関連分類
HY-P991935 関連分類
Powered by Bioz
- ANT1034
- ANT 1034
- ANT-1034
- Apoptosis
- CD4? T cell proliferation
- Raji Burkitt lymphoma xenograft
- apoptosis
- b cell malignancies
- SCID mouse/human CD52 tumour xenograft model
- complement dependent cell cytotoxicity
- T cell proliferation
- REH++ cells
- cancer
- Fox Chase SCID mice
- antibody dependent cell cytotoxicity
- crosslinking antibody
- human peripheral blood mononuclear cells
- alemtuzumab
- CD52
- Inhibitor
- inhibitor
- inhibit